Univariate Cox proportional hazards analyses of predictors of 1- to 180-d VTE recurrence among Olmsted County, MN residents with a first-lifetime VTE diagnosed in 1984-1997
| Variable . | HR (95%CI) [P] . |
|---|---|
| Age, y (per decade increase) | 1.03 (0.92, 1.15) [.59] |
| Female sex | 1.25 (0.81, 1.93) [.32] |
| BMI, kg/m2 per 10 kg/m2 increase | 1.11 (0.82, 1.51) [.50] |
| BMI, kg/m2 | [.07] |
| < 20 | 0.15 (0.02, 1.12) |
| 20, < 25 | Referent |
| 25, < 30 | 1.00 (0.60, 1.69) |
| ≥ 30 | 0.86 (0.49, 1.51) |
| Active cancer | 2.63 (1.69, 4.08) [< .01] |
| Neurologic disease with leg paresis | 2.65 (1.44, 4.88) [< .01] |
| Recent neurosurgery | 2.61 (1.14, 5.99) [.02] |
| Daily mean APTT, s per 10-s increase | 0.96 (0.89, 1.03) [.24] |
| Daily mean PT, s | 0.98 (0.95, 1.02) [.30] |
| INR | 1.02 (0.92, 1.13) [.70] |
| Daily mean platelet count, ×109/L per 20 × 109/L increase | 0.99 (0.95, 1.02) [.52] |
| Daily mean hemoglobin, g/L | 0.87 (0.77, 0.98) [.02] |
| Time from VTE onset to start of heparin, d | 0.99 (0.95, 1.04) [.82] |
| Started heparin therapy | 0.85 (0.46, 1.57) [.61] |
| APTT ≥ 58 s within 24 ± 4 h of starting heparin | 0.40 (0.24, 0.65) [< .01] |
| APTT ≥ 40 s within 24 ± 4 h of starting heparin | 0.44 (0.22, 0.89) [.02] |
| Proportion of time on heparin with APTT ≥ 58 s per 10% increase* | 0.92 (0.86, 0.99) [.02] |
| Proportion of time on heparin with APTT ≥ 40 s per 10% increase† | 0.87 (0.82, 0.93) [< .001] |
| Warfarin | 0.30 (0.19, 0.47) [< .01] |
| Duration of heparin/warfarin overlap, d | 0.97 (0.91, 1.04) [.43] |
| Proportion of time on warfarin with INR ≥ 1.5 per 10% increase | 0.90 (0.84, 0.97) [< .01] |
| Proportion of time on warfarin with INR ≥ 2.0 per 10% increase | 0.89 (0.82, 0.96) [< .01] |
| Inferior vena cava filter placement | 3.98 (2.33, 6.77) [< .01] |
| Variable . | HR (95%CI) [P] . |
|---|---|
| Age, y (per decade increase) | 1.03 (0.92, 1.15) [.59] |
| Female sex | 1.25 (0.81, 1.93) [.32] |
| BMI, kg/m2 per 10 kg/m2 increase | 1.11 (0.82, 1.51) [.50] |
| BMI, kg/m2 | [.07] |
| < 20 | 0.15 (0.02, 1.12) |
| 20, < 25 | Referent |
| 25, < 30 | 1.00 (0.60, 1.69) |
| ≥ 30 | 0.86 (0.49, 1.51) |
| Active cancer | 2.63 (1.69, 4.08) [< .01] |
| Neurologic disease with leg paresis | 2.65 (1.44, 4.88) [< .01] |
| Recent neurosurgery | 2.61 (1.14, 5.99) [.02] |
| Daily mean APTT, s per 10-s increase | 0.96 (0.89, 1.03) [.24] |
| Daily mean PT, s | 0.98 (0.95, 1.02) [.30] |
| INR | 1.02 (0.92, 1.13) [.70] |
| Daily mean platelet count, ×109/L per 20 × 109/L increase | 0.99 (0.95, 1.02) [.52] |
| Daily mean hemoglobin, g/L | 0.87 (0.77, 0.98) [.02] |
| Time from VTE onset to start of heparin, d | 0.99 (0.95, 1.04) [.82] |
| Started heparin therapy | 0.85 (0.46, 1.57) [.61] |
| APTT ≥ 58 s within 24 ± 4 h of starting heparin | 0.40 (0.24, 0.65) [< .01] |
| APTT ≥ 40 s within 24 ± 4 h of starting heparin | 0.44 (0.22, 0.89) [.02] |
| Proportion of time on heparin with APTT ≥ 58 s per 10% increase* | 0.92 (0.86, 0.99) [.02] |
| Proportion of time on heparin with APTT ≥ 40 s per 10% increase† | 0.87 (0.82, 0.93) [< .001] |
| Warfarin | 0.30 (0.19, 0.47) [< .01] |
| Duration of heparin/warfarin overlap, d | 0.97 (0.91, 1.04) [.43] |
| Proportion of time on warfarin with INR ≥ 1.5 per 10% increase | 0.90 (0.84, 0.97) [< .01] |
| Proportion of time on warfarin with INR ≥ 2.0 per 10% increase | 0.89 (0.82, 0.96) [< .01] |
| Inferior vena cava filter placement | 3.98 (2.33, 6.77) [< .01] |